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demonstrate radiosensitization following molecular inhibition of EGFR 
signaling. 
Methods: We report a phase II trial testing the combination of C225 
with CRT in unresectable stage III NSCLC with a planned sample 
size of 84 PTS. Eligibility criteria included Zubrod performance status 
(PS) ≤ 1, weight loss ≤ 5% over past 3 months, FEV1 ≥ 1.2 l, adequate 
hematologic, hepatic, and renal function. PTS received an initial dose 
of C225 (400 mg/m2) on day 1 of week 1, then weekly doses of C225 
(250 mg/m2) until completion of therapy (weeks 2 – 17). During week 
2, PTS started CRT (63 Gy/35 fractions) with weekly carboplatin (C) 
AUC 2 and paclitaxel (P) 45 mg/m2 x 6 doses followed by C (AUC 6) 
and P (200 mg/m2) x 2 cycles (weeks 12-17). Interim monitoring for 
severe (grade ≥ 3) or excessive non-hematologic toxicities occurred 
after PTS had been treated and followed for at least 90 days after RT. 
Primary endpoints include safety and compliance of concurrent C225 
and CRT. 
Results: 93 PTS were enrolled with 87 evaluable PTS. PTS character-
istics: 57% male, median age 64 years (range 42-85), 47% PS 0, 46% 
stage IIIA. Median follow-up is 17.6 months. Response rate is 62% 
(n=54) and 18 month overall survival (OS) is 54.7%(# at risk=39). 
Adverse events related to treatment include 20%(n=17) of PTS with 
grade 4 hematologic toxicities and 7 PTS who had grade 3 esophagi-
tis. There was 1 infection related death, 1 death NOS, and 3 PTS who 
died of pulmonary complications (adult respiratory distress syndrome, 
pneumonitis, and hypoxia). 
Conclusions: The combination of C225 with CRT is feasible. Further 
study will be needed to determine whether the addition C225 to CRT 
enhances toxicity or efﬁcacy. Complete compliance and toxicity data 
along with median survival will be reported.
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Background: Smoking is the second major cause of death in the world. 
If current smoking patterns continue, it will cause 10 million deaths/
year by 2020. The aim of the present study is to estimate the mortality 
and DALYs (disability adjusted life years) directly related to smok-
ing in Portugal focused on the most frequent diseases associated with 
smoking, as well as the mortality and DALYs potential reduction with 
smoking cessation.
Methods: The methodology used is that of the WHO and the World 
Bank. The process involves two steps: identiﬁcation of diseases closely 
associated with smoking coded in the International Classiﬁcation of 
Diseases, and determining the quantitative relation between smok-
ing and the identiﬁed diseases using the epidemiological concepts of 
relative risk and population attributable risk. As the risk for ex-smok-
ers will never be the same as nonsmokers we determined the burden 
related to mortality if smoking ceased at present.
Results: The investigation of burden of disease from mortality at-
tributable to smoking was based on analysis of data from the National 
Statistics Institute for the year 2004. There were 6.565 DALYs lost per 
100.000. The group of diseases related to smoking is responsible for 
50% of the deaths and 39% of the DALYs. Twelve percent of the total 
disease burden due to mortality and DALYs is attributable to smoking, 
being higher for men (16% of DALYs) than for women (4%). If smok-
ing was abandoned, the burden of disease would be reduced by 53% 
(54% in men; 65% in women).
Conclusions: Twelve percent of the overall disease burden and mortal-
ity is attributable to smoking. The health gains obtained by reducing 
tobacco consumption could reach 50%. This highlights the importance 
of smoking cessation as a priority in health policies.
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Background: Occupational carcinogens occupy a special place among 
the different classes of human carcinogens. The aim of this study was 
to estimate the fraction of lung cancer incidence attributed to occupa-
tional exposures to Silica, Cadmium, Nickel, Arsenic, Chromium, Die-
sel Fumes, Beryllium, and Asbestos (the best established lung cancer 
carcinogens in the workplace).
Methods: Exposure to each of the mentioned carcinogens at national 
level was estimated using workforce data estimated by the population 
census 1995 and obtained from the ILO. The prevalence of exposure 
for each industry/ carcinogens was estimated using exposure data from 
the CAREX database (CAREX is an international information system 
on occupational exposure to known and suspected carcinogens kept and 
maintained by EU). The magnitude of relative risk of lung cancer for 
each carcinogen of interest was estimated from local and international 
literatures. The Levin modiﬁed population attributable risk (incidence) 
fraction was utilized to estimate the fraction of lung cancer incidence as 
estimated by the Tehran Population Based Cancer Registry that could 
be attributed to workplace exposure of carcinogens of interest. 
Results: The crude incidence of lung cancer was 10.4 and 5 per 
100.000 populations of male and female, respectively. Total workforce 
according to the 1995 census was 13165489 of which 12488020 were 
male and 677469 were female. Agricultural sectors with 25% hold the 
most frequent number of workforce and electrical related sector with 
0.01% hold the least frequent number of workforce. After applying the 
CAREX exposure estimate to each sector, the proportion of male work-
ers exposed to lung carcinogen was 0.08 and this ﬁgure was 0.02 for 
females. Estimating a relative risk of 1.9 for high exposure and 1.5 for 
low exposure and employing The Levin modiﬁed formula, the fraction 
of lung cancer attributed to carcinogens in the workplace among female 
was 0.015 with a 95% CI of (0.012 to 0.019) and this ﬁgures were 0.12 
with 95%CI of (0.10 to 0.15) for male. These fractions correspond to an 
estimated incidence of 1.12 cases lung cancer per 100,000 populations 
among male and 0.8 cases of lung cancer among 100,000 population of 
female. Table 3 Show Proportion of workers exposed to lung carcino-
gens, by industry based on the CAREX estimates.
